R. Bryan Barriger, MD

home / authors / r-bryan-barriger-md

Articles

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Joe Yujiao Chang, MD, PhD;Larry L. Kestin, MD;R. Bryan Barriger, MD;Indrin J. Chetty, PhD;Mark E. Ginsburg, MD;Sanath Kumar, MD;Billy W. Loo, Jr, MD, PhD;Benjamin Movsas, MD;Andreas Rimner, MD;Kenneth E. Rosenzweig, MD;Thomas E. Stinchcombe, MD;Gregory M. M. Videtic, MD, CM;Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Advanced Radiation Technology in the Treatment of Anal Cancer

R. Bryan Barriger, MD;Peter A. S. Johnstone, MD

November 14th 2009

Dr. Czito and colleagues provide an intriguing overview on adapting and using more technically advanced techniques to deliver radiation therapy for anal cancer patients. The paper starts with a brief history of the treatment of anal cancer, moving from abdominoperineal resection to combined-modality therapy with radiation and chemotherapy and discusses the trials showing that combined chemoradiotherapy is superior to radiation alone in terms of local control and colostomy-free survival.[1,2] Adding mitomycin to fluorouracil (5-FU) has been scrutinized for increasing toxicity but has been shown to decrease colostomy rates compared to cisplatin/5-FU or 5-FU alone.[3,4]